Hello, Welcome to Shine Consultant !
Summit & Event Shine Speaker Bureau Shine Advisor Shine Event Service
  • Summit & Event :
    With field research of markets and industries which is analyzed from a global strategic perspective by our professional teams, as well as hot topics which interest leadership and management, Shine Consultant provides you with one-stop platform of dialogue, practice -sharing and social network!
  • Shine Speaker Bureau:
    Committed to provide keynote speakers, executive learning masterclasses and boardroom advisory for global enterprises and institutions, each service provides a deeper and more interactive experience, especially for small, selected audiences and key individuals. We have the resources of the most influential business leaders and experts, who are the most outstanding representatives in their fields. Our team consists of experienced speech and event managers, and we focus on building long-term and in-depth partnerships.
  • Shine Advisor:
    As world-class insight network, we connects clients-decision makers with vetted subject matter experts-advisors. Our clients leverage the insights and perspectives shared by our advisors to stay informed and make better business decisions.We have over 600,000 Shine Advisors in 20 industries, which continues to grow every day.
  • Shine Event Service:
    Committed to be the world's most professional provider of industrial Summit & Event. We provide one-stop professional services, including investigating and planning, on-demand inviting, marketing and promoting, operating, project management, live& digital conference, each service is performed by an experienced professional team matched with long-term industrial resources. We focus on establishing long-term and in-depth partnerships.
Guest Information
 Li Chen
Li Chen
Positions:

President & CEO 

Company:

Hua Medicine (Shanghai) Ltd.

Dr. Li Chen is the co-founder and CEO of Hua Medicine, a clinical stage China biotech company focuses on discovery and development and commercialization of clinically differentiated medicines for patients worldwide. He is a pioneer in collaborative innovation in China and advanced VIC model to VIC+Q that ensured successful POC of a first-in-class GKA in China for T2D.  Hua Medicine leverages global resources to develop GKA and completed four clinical studies in China and USA, in which the T2DM medicine demonstrated desirable safety and efficacy profiles together with a validation of beta cell function improvement in Chinese T2DM patients.  The PhII clinical study of this innovative medicine has been completed in 3Q2016, and Ph III clinical study in China has been launched in 2017.